A new analysis of the 17,604-patient SELECT trial found that changes in weight, waist size, blood pressure and blood markers accounted for at most about half of the drug's reduction in cardiovascular events.
A nationwide study in The BMJ found a higher risk of venous blood clots with any oral hormone therapy, while treatment through the skin showed no general increase. The absolute risks are small.
A genetic analysis led by Arizona State University suggests the H5N1 variant began expanding around summer 2024, before its first recognised detection that September. The authors call for faster sequencing and better-coordinated surveillance.